ADH1B and neoplasm: High ADH1B (Supplementary Fig. 2i) but low FAP (Supplementary Fig. 2j) expression after neoadjuvant treatment might indicate the main contribution of ADH1B + CAF to fibroblasts, potentially enhancing anti-tumor immune activity.